<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inmed Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc</link>
<description>Latest news and press releases for Inmed Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inmed-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583ed78dffbe2df0fce51.webp</url>
<title>Inmed Pharmaceuticals Inc</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc</link>
</image>
<item>
<title>InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-receives-nasdaq-notification-regarding-minimum-bid-price-compliance</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-receives-nasdaq-notification-regarding-minimum-bid-price-compliance</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a research, development,</description>
</item>
<item>
<title>InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-announces-positive-data-from-human-brain-organoid-neuroinflammation-models-supporting-the-inm-901-alzheimers-disease-program</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-announces-positive-data-from-human-brain-organoid-neuroinflammation-models-supporting-the-inm-901-alzheimers-disease-program</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate</description>
</item>
<item>
<title>InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-provides-update-on-pharmaceutical-development-programs-advancing-lead-drug-candidates-towards-ind-and-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-provides-update-on-pharmaceutical-development-programs-advancing-lead-drug-candidates-towards-ind-and-clinical-trial</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1</description>
</item>
<item>
<title>InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-provides-update-on-baymedica-operations-and-strengthens-focus-on-pharmaceutical-development-pipeline-4</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-provides-update-on-baymedica-operations-and-strengthens-focus-on-pharmaceutical-development-pipeline-4</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company</description>
</item>
<item>
<title>InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-reports-second-quarter-fiscal-222300047</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-reports-second-quarter-fiscal-222300047</guid>
<pubDate>Wed, 11 Feb 2026 22:23:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025.The Company's full financial statements and related MD&A for the second quarter ended...</description>
</item>
<item>
<title>InMed Announces Results of 2025 Annual General and Special Meeting</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-announces-results-2025-annual-010000325</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-announces-results-2025-annual-010000325</guid>
<pubDate>Thu, 18 Dec 2025 01:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in...</description>
</item>
<item>
<title>InMed Provides Update on BayMedica Commercial Business</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-provides-baymedica-commercial-business-223100813</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-provides-baymedica-commercial-business-223100813</guid>
<pubDate>Fri, 12 Dec 2025 22:31:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") was...</description>
</item>
<item>
<title>InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-announces-successful-completion-pharmacokinetic-123000508</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-announces-successful-completion-pharmacokinetic-123000508</guid>
<pubDate>Tue, 18 Nov 2025 12:30:00 GMT</pubDate>
<description>Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today announced the successful..</description>
</item>
<item>
<title>InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-reports-first-quarter-fiscal-215100350</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-reports-first-quarter-fiscal-215100350</guid>
<pubDate>Thu, 06 Nov 2025 21:51:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of fiscal year 2026, which ended September 30, 2025.The Company's full financial statements and related MD&A for the first quarter ended...</description>
</item>
<item>
<title>InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-appoints-mr-john-123000105</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-appoints-mr-john-123000105</guid>
<pubDate>Thu, 16 Oct 2025 12:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately.Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 years in...</description>
</item>
<item>
<title>Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-appoints-mr-john-bathery-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-appoints-mr-john-bathery-to-its-board-of-directors</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical</description>
</item>
<item>
<title>InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-appoints-mr-neil-123000346</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-appoints-mr-neil-123000346</guid>
<pubDate>Thu, 09 Oct 2025 12:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately.Mr. Klompas brings over 30 years of experience in healthcare and biotechnology across operational,...</description>
</item>
<item>
<title>InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-reports-full-fiscal-123000089</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-reports-full-fiscal-123000089</guid>
<pubDate>Tue, 23 Sep 2025 12:30:00 GMT</pubDate>
<description>Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathologyFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular DegenerationCash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on...</description>
</item>
<item>
<title>InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-to-present-at-the-life-sciences-virtual-investor-forum-september-18th-2025</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-to-present-at-the-life-sciences-virtual-investor-forum-september-18th-2025</guid>
<pubDate>Tue, 16 Sep 2025 17:39:00 GMT</pubDate>
<description>Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed’s CEO, will present live at the Life</description>
</item>
<item>
<title>InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-participate-h-c-wainwright-173300779</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-participate-h-c-wainwright-173300779</guid>
<pubDate>Fri, 05 Sep 2025 17:33:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of InMed's management team will also be conducting..</description>
</item>
<item>
<title>InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-present-inm-901-data-110000515</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-present-inm-901-data-110000515</guid>
<pubDate>Mon, 28 Jul 2025 11:00:00 GMT</pubDate>
<description>Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer</description>
</item>
<item>
<title>InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-announces-closing-5-110000426</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-announces-closing-5-110000426</guid>
<pubDate>Fri, 27 Jun 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and</description>
</item>
<item>
<title>InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-announces-5-million-120000446</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-pharmaceuticals-announces-5-million-120000446</guid>
<pubDate>Wed, 25 Jun 2025 12:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term pre</description>
</item>
<item>
<title>InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmeds-inm-901-significantly-reduces-110000270</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmeds-inm-901-significantly-reduces-110000270</guid>
<pubDate>Tue, 24 Jun 2025 11:00:00 GMT</pubDate>
<description>Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie</description>
</item>
<item>
<title>InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA</title>
<link>https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-appoints-cbiz-auditor-connection-203000809</link>
<guid isPermaLink="true">https://6ix.com/company/inmed-pharmaceuticals-inc/news/inmed-appoints-cbiz-auditor-connection-203000809</guid>
<pubDate>Fri, 13 Jun 2025 20:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Marcum LLP has resigned as InMed's auditor following the acquisition of Marcum's attest business by CBIZ CPAs P.C., with an effective resignation date of June 12, 2025 (the "Marcum Acquisition"). As</description>
</item>
</channel>
</rss>